Societies

Carlos Torrado: Excited to present our poster at ASCO24

Photo taken from NCI CTEP Clinical Research/X

Jun 1, 2024, 12:11

Carlos Torrado: Excited to present our poster at ASCO24

Carlos Torrado, Clinical Fellow at MD Anderson Cancer Center, recently shared a post by NCI CTEP Clinical Research on X, adding:

“Excited to present our poster tomorrow at the ASCO meeting in collaboration with NCI CTEP!”

Quoting NCI CTEP Clinical Research’s post:

“ASCO24 abstract for ongoing ETCTN (10449).

Phase 1 study of BET inhibitor ZEN003694 in combination with MEK1/2 inhibitor binimetinib in solid tumors with RAS pathway alterations and triple-negative breast cancer”

Read further
Sources: Carlos Torrado/X and NCI CTEP Clinical Research/X

2024 Annual Meeting of ASCO ASCO ASCO24 binimetinib cancer Carlos Torrado ETCTN MEK1/2 inhibitor NCI CTEP Clinical Research OncoDaily Oncology RAS pathway solid tumors triple-negative breast cancer

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage